噻吗洛尔滴眼液在急性房角关闭危象序贯治疗中的疗效

doi:10.3969/j.issn.1674-490X.2024.01.005

医学研究与教育 ›› 2024, Vol. 41 ›› Issue (1): 34-40.DOI: 10.3969/j.issn.1674-490X.2024.01.005

噻吗洛尔滴眼液在急性房角关闭危象序贯治疗中的疗效

陈光¹,李雪静²,王凤娟¹,游冀鹏¹,石荣兴³

1.河北大学附属医院眼科, 河北保定 071000;
2.顺平县人民医院眼科, 河北顺平 072250;
3.容城县人民医院眼科, 河北容城 071700

收稿日期:2023-11-23 出版日期:2024-02-25 发布日期:2024-02-25
作者简介:陈光(1981—),男,河北容城人,副主任医师,硕士,主要从事眼科疾病的诊疗和教学工作。 E-mail: gch747@163.com
基金资助:
河北省医学科学研究课题计划项目(20210907);保定市科学技术研究与发展计划项目(2041ZF165)

Received:2023-11-23 Online:2024-02-25 Published:2024-02-25

摘要/Abstract

摘要： 目的观察噻吗洛尔滴眼液在急性房角关闭危象序贯治疗中的疗效。方法前瞻性随机双盲病例对照研究。连续纳入2021年4月至2023年10月河北大学附属医院诊断为急性房角关闭危象(acute angle-closure crisis,AACC)的患者,收集其病例资料并以随机数字表法分为应用噻吗洛尔组(A组)与安慰剂组(B组)。所有患者序贯应用药物治疗、前房穿刺、激光周边虹膜成形术,以治疗后2 h、4 h、6 h为治疗节点,记录并统计在各个节点2组患者的眼压下降值、AACC得到控制的眼数及所需时间。结果在序贯治疗后2 h、4 h、6 h的3个节点,A组的眼压下降值分别为(13.87±13.85 )mmHg(1 mmHg=0.133 kPa)、(28.42±12.87)mmHg、(35.69±8.51)mmHg,AACC得到控制的眼数分别为23眼(29.87%)、51眼(66.23%)、71眼(92.20%);B组的眼压下降值分别为(15.88±14.95)mmHg、(28.17±13.63)mmHg、(33.90±13.59)mmHg,AACC得到控制的眼数分别为30眼(36.59%)、58眼(70.73%)、75眼(91.46%);治疗有效的患者中,AACC控制的时间A组为(3.29±1.31)h,B组为(3.38±1.34)h。2组患者在序贯治疗各个节点的眼压下降值、AACC缓解的眼数及病情缓解所需时间差异均无统计学意义(P>0.05 )。结论在AACC的序贯治疗过程中,噻吗洛尔滴眼液对于提高治疗成功率无明显帮助。

关键词: 原发性闭角型青光眼, 急性房角关闭危象, 噻吗洛尔滴眼液, 序贯治疗, 病例对照研究

Abstract: Objective To observe and compare the efficacy of timolol eye drops in sequential treatment of acute angle-closure crisis. Methods In this prospective, randomized, double-blind case-control study, patients diagnosed with acute angle-closure crisis(AACC)at the Affiliated Hospital of Hebei University from April 2021 to October 2023 were continuously enrolled. The patient data were collected and randomly divided into timolol group(group A)and placebo group(group B). All patients were sequentially treated with drug therapy, anterior chamber paracentesis and argon laser peripheral iridoplasty. The primary outcomes were decreased intraocular pressure, success rate, and treatment time. Results At 2 hours, 4 hours and 6 hours after the start of treatment, the reduction of intraocular pressure(IOP)in group A were(13.87±13.85)mmHg(1 mmHg=0.133 kPa),(28.42±12.87)mmHg and(35.69±8.51)mmHg respectively, the number of controlled eyes were 23 eyes(29.87%), 51 eyes(66.23%)and 71 eyes(92.20%)respectively. The reduction of IOP in group B were(15.88±14.95)mmHg,(28.17±13.63)mmHg,(33.90±13.59)mmHg respectively, the number of controlled eyes were 30 eyes(36.59%), 58 eyes(70.73%)and 75 eyes(91.46%)respectively. Among patients whose crisis were relieved, the times for AACC relief were(3.29±1.31)hours in group A and(3.38±1.34)hours in group B. There were no significant differences in IOP reduction, numbers of eyes remission and times for AACC relief between the two groups at each point of sequential treatment(P>0.05 ). Conclusion In the sequential treatment of AACC, timolol is not helpful to improve the success rate of treatment.

Key words: primary angleclosure glaucoma, acute angle-closure crisis, timolol eye drops, sequential therapy, case-control study

中图分类号:

陈光,李雪静,王凤娟,游冀鹏,石荣兴. 噻吗洛尔滴眼液在急性房角关闭危象序贯治疗中的疗效[J]. 医学研究与教育, 2024, 41(1): 34-40.

参考文献

[1] PRUM B E, HERNDON L W, MOROI S E, et al. Primary angle closure preferred practice pattern(®)guidelines[J]. Ophthalmology, 2016, 123(1): P1-P40. DOI: 10.1016/j.ophtha.2015.10.049.
[2] WU A M, STEIN J.D, SHAH M. Potentially missed opportunities in prevention of acute angle-closure crisis[J]. JAMA Ophthalmol, 2022, 140(6): 598-603. DOI: 10.1001/jamaophthalmol.2022.1231.
[3] WAGNER I V, STEWART M W, DORAIRAJ S K. Updates on the diagnosis and management of glaucoma[J]. Mayo Clin Proc Innov Qual Outcomes, 2022, 6(6): 618-635. DOI: 10.1016/j.mayocpiqo.2022.09.007.
[4] 姬俊雅,于浩南,栾莉,等.急性发作期高眼压持续时间对闭角型青光眼患者的影响: 基于OCTA的研究[J].眼科新进展, 2022, 42(5): 378-381. DOI: 10.13389/j.cnki.rao.2022.0076.
[5] SINGH P, RIJAL A P. Effectivity of Nd Yag PI in treatment of acute primary angle closure glaucoma[J]. Nepal Med Coll J, 2014, 16(1): 45-49.
[6] 熊飞,程杰,于璐,等.半导体532 nm虹膜激光治疗药物难控制原发性急性闭角型青光眼急性发作期观察[J].国际眼科杂志, 2016, 16(9): 1738-1739. DOI: 10.3980/j.issn.1672-5123.2016.9.37.
[7] 刘涛,乔春艳,许欣悦, 等.青光眼住院患者疾病构成变化的分析[J].中华眼科杂志, 2017, 53(8): 610-615. DOI: 10.3760/cma.j.issn.0412-4081.2017.08.009.
[8] 中华医学会眼科学分会青光眼学组.中国原发性闭角型青光眼诊治方案专家共识(2019年)[J].中华眼科杂志, 2019, 55(5): 325-328. DOI: 10.3760/cma.j.issn.0412-4081.2019.05.002.
[9] RIBEIRO M, BARBOSA-BREDA J, GONCALVES F, et al. Evaluation of the manchester triage system in patients with acute primary angle closure attack: a retrospective study[J]. Acta Med Port, 2023, 36(11): 698-705. DOI: 10.20344/amp.19170.
[10] SIHOTA R, ANGMO D, RAMASWAMY D, et al. Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma[J]. Indian J Ophthalmol, 2018, 66(4): 495-505. DOI: 10.4103/ijo.IJO_1130_17.
[11] CHAN P P, PANG J C, THAM C C. Acute primary angle closure-treatment strategies, evidences and economical considerations[J]. Eye(Lond), 2019, 33(1): 110-119. DOI: 10.1038/s41433-018-0278-x.
[12] 肖婷婷,石珂,缪振忠,等.临床抗青光眼药物的新进展[J].眼科新进展, 2019, 39(2): 192-196. DOI: 10.1016/j.ajo.2017.11.019.
[13] CHABI A, VARMA R, TSAI J C, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension[J]. Am J Ophthalmol, 2012, 153(6): 1187-1196. DOI: 10.1016/j.ajo.2011.11.008.
[14] LAZREG S, MERAD Z, NOURI M T, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications[J]. J Fr Ophtalmol, 2018, 41(10): 945-954. DOI: 10.1016/j.jfo.2018.04.012.
[15] PISELLA P J, POULIQUEN P, BAUDOUIN C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication[J]. Br J Ophthalmol, 2002, 86(4): 418-423. DOI: 10.1136/bjo.86.4.418.
[16] LITORIYA A, TIWARI U S, PATHAK R. Effect of various topical anti glaucoma drugs on cardiopulmonary system. A prospective study[J]. Rom J Ophthalmol, 2019, 63(2): 142-145.
[17] WANG Y, DONG X X, HOU X W, et al. Risk factors for primary angle-closure glaucoma: a systematic review and meta-analysis of 45 studies[J]. Optom Vis Sci, 2023, 100(9): 606-613. DOI: 10.1097/OPX.0000000000002050.
[18] ZENG H B, JIANG J D, LI R, et al. The inflammatory cytokine profiles and ocular biometric characteristics of primary angle-closure glaucoma[J]. J Int Med Res, 2023, 51(1): 665758934. DOI: 10.1177/03000605221147434.

噻吗洛尔滴眼液在急性房角关闭危象序贯治疗中的疗效

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	张彩芬,尹轶广,刘辉,马立新. 保定市出生缺陷的影响因素[J]. 医学研究与教育, 2011, 28(6): 37-40.
[2]	安海水,姚军,陈静,李永乐,郝明珠,徐新辉. 颈源性头痛的诊断与序贯治疗[J]. 医学研究与教育, 2010, 27(6): 41-43.